Michael T. Schweizer

Author

Also Known As

M Schweizer, M. Schweizer, M. T. Schweizer, M.T. Schweizer, Michael Schweizer, Michael T Schweizer, Michael T. Schweizer, Michael Thomas Schweizer, Schweizer, Michael

371

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University University of Michigan

About

Michael T. Schweizer is an author at Fred Hutch Cancer Center specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	27	1.8K
2	Cell Biology	5	5	669
3	Engineering	3	3	129
4	Health Sciences	1	1	439
5	Public Health	1	1	31

Michael T. Schweizer

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling Eric G. Bluemn, Ilsa M. Coleman, Jared M. Lucas, Cancer Cell UrologyHormonal ReceptorFibroblast Growth FactorFgf SignalingProstatic Disease	2017	733
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer Mark P. Labrecque, Ilsa M. Coleman, Lisha G. Brown, Journal of Clinical Investigation Scnpc Pdx ModelsUrologyStratifies Diverse PhenotypesGenitourinary CancerTumor Heterogeneity	2019	439
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study Michael T. Schweizer, Emmanuel S. Antonarakis, Hao Wang, Science Translational Medicine	2015	250
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Journal of Clinical Investigation	2018	203
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study Benjamin A. Teply, Hao Wang, Brandon Luber, The Lancet Oncology Bipolar Androgen TherapyUrologyOncologyMulticohort StudyMedicine	2017	192
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, JAMA Oncology	2021	184
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations Catherine H. Marshall, Alexandra Sokolova, Andrea McNatty, European Urology UrologyGenitourinary CancerMedicineOlaparib TreatmentCancer Treatment	2019	157
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference Kendal Jensen, Eric Q. Konnick, Michael T. Schweizer, JAMA Oncology	2020	153
MSH2 Loss in Primary Prostate Cancer Liana B. Guedes, Emmanuel S. Antonarakis, Michael T. Schweizer, Clinical Cancer Research	2017	149
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer Michael T. Schweizer, Xian Zhou, Hao Wang, European Urology UrologyOncologyMedicineBenign Prostatic HyperplasiaPharmacotherapy	2014	135

Page 1